false
--12-31
0001506983
0001506983
2025-02-03
2025-02-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): February 3, 2025
GLUCOTRACK,
INC.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-41141 |
|
98-0668934 |
| (State
or Other Jurisdiction |
|
(Commission |
|
(IRS
Employer |
| of
Incorporation) |
|
File
Number) |
|
Identification
No.) |
| 301
Rte 17 North, Ste. 800, Rutherford, NJ |
|
07070 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (201) 842-7715
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock |
|
GCTK |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §
230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Glucotrack,
Inc., a Delaware corporation (the “Company”), filed with the Delaware Secretary of State a Certificate of Amendment to the
Certificate of Incorporation of the Company (the “Certificate of Amendment”), which became effective at 4:30 p.m. on February
3, 2025 (the “Effective Time”), to effect a one-for-twenty (1:20) reverse stock split (the “Reverse Stock Split”),
of the shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”). The Reverse Stock Split
was approved by the Company’s stockholders at the special meeting of the stockholders on January 3, 2025.
As
a result of the Reverse Stock Split, every 20 shares of issued and outstanding Common Stock will be automatically combined into one (1)
issued and outstanding share of Common Stock, without any change in the par value per share. No fractional shares were issued as a result
of the Reverse Stock Split. Instead, stockholders who otherwise would have been entitled to receive fractional shares because they held
a number of shares not evenly divisible by the Reverse Stock Split ratio were entitled to receive an additional fraction of a share of
Common Stock to round up to the next whole share.
Following
the Reverse Stock Split, the number of shares of Common Stock outstanding was proportionally reduced from 155,491,473 shares to approximately
7,774,574 shares. The shares of Common Stock underlying the Company’s outstanding stock options and warrants will be similarly
adjusted along with corresponding adjustments to their exercise prices.
The
Company’s transfer agent, VStock Transfer, LLC, is the exchange agent for the Reverse Stock Split and will correspond with stockholders
of record regarding the Reverse Stock Split. Stockholders owning shares via a broker or other nominee will have their positions automatically
adjusted to reflect the Reverse Stock Split.
The
Common Stock will begin trading on a reverse stock split-adjusted basis upon market open on February 4, 2025. The ticker symbol for the
Common Stock will remain “GCTK.” The new CUSIP number for the Common Stock following the Reverse Stock Split will be 45824Q705.
The
forgoing description of the Certificate of Amendment does not purport to be complete and is subject to, and is qualified in its entirety
by reference to, the full text of the Certificate of Amendment which is attached as Exhibit 3.1 to this Current Report on Form 8-K, and
is incorporated herein by reference.
Item 7.01 Regulation FD Disclosure
On
February 4, 2025, the Company issued a press release (the “Press Release”) announcing the completion of the Company’s
first in-human clinical study of its continuous blood glucose monitor. The Press Release is furnished as Exhibit 99.1 and incorporated
into this Item 7.01 by reference.
The
information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, and shall not be deemed incorporated by reference into any filing with the Securities and Exchange
Commission, except as expressly set forth by specific reference in such a filing.
Item
8.01 Other Events
The
table below sets forth the impact of the Reverse Stock Split on the Company’s net loss per common share - basic and diluted;
weighted average common shares outstanding - basic and diluted; and shares issued and outstanding, for the years ended December
31, 2023 and 2022; the three months ended March 31, 2024 and 2023, the three and six months ended June 30, 2024 and 2023, and the
three and nine months ended September 30, 2024 and 2023.
| |
|
In thousands of US Dollars |
|
| |
|
(except stock and per stock amounts) |
|
| |
|
PRE SPLIT (1) |
|
|
POST SPLIT (1) |
|
| |
|
YEAR ENDED DECEMBER 31, |
|
|
YEAR ENDED DECEMBER 31, |
|
| |
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
| Comprehensive net loss |
|
$ |
(7,098 |
) |
|
$ |
(4,412 |
) |
|
$ |
(7,098 |
) |
|
$ |
(4,412 |
) |
| Net loss per common share - basic |
|
$ |
(0.38 |
) |
|
$ |
(0.29 |
) |
|
$ |
(34.19 |
) |
|
$ |
(28.51 |
) |
| Net loss per common share - diluted |
|
$ |
(0.38 |
) |
|
$ |
(0.29 |
) |
|
$ |
(34.19 |
) |
|
$ |
(28.51 |
) |
| Weighted average common shares outstanding - basic |
|
|
20,760,266 |
|
|
|
15,474,600 |
|
|
|
207,603 |
|
|
|
154,746 |
|
| Weighted average common shares outstanding - diluted |
|
|
20,760,266 |
|
|
|
15,474,600 |
|
|
|
207,603 |
|
|
|
154,746 |
|
| Common stock outstanding at year end |
|
|
20,892,193 |
|
|
|
15,550,730 |
|
|
|
208,922 |
|
|
|
155,008 |
|
| |
|
In thousands of US Dollars |
|
| |
|
(except stock and per stock amounts) |
|
| |
|
PRE SPLIT (2) |
|
|
POST SPLIT (2) |
|
| |
|
3 MONTHS ENDED MARCH 31, |
|
|
3 MONTHS ENDED MARCH 31, |
|
| |
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
| Comprehensive net loss |
|
$ |
(2,921 |
) |
|
$ |
(1,281 |
) |
|
$ |
(2,921 |
) |
|
$ |
(1,281 |
) |
| Net loss per common share - basic |
|
$ |
(0.12 |
) |
|
$ |
(0.08 |
) |
|
$ |
(11.70 |
) |
|
$ |
(8.26 |
) |
| Net loss per common share - diluted |
|
$ |
(0.12 |
) |
|
$ |
(0.08 |
) |
|
$ |
(11.70 |
) |
|
$ |
(8.26 |
) |
| Weighted average common shares outstanding - basic |
|
|
24,959,768 |
|
|
|
15,503,632 |
|
|
|
249,598 |
|
|
|
155,036 |
|
| Weighted average common shares outstanding - diluted |
|
|
24,959,768 |
|
|
|
15,503,632 |
|
|
|
249,598 |
|
|
|
155,037 |
|
| Common stock outstanding at period end |
|
|
26,756,369 |
|
|
|
15,503,632 |
|
|
|
267,564 |
|
|
|
155,037 |
|
| |
|
In thousands of US Dollars |
|
| |
|
(except stock and per stock amounts) |
|
| |
|
PRE SPLIT (3) |
|
|
POST SPLIT (3) |
|
| |
|
3 MONTHS ENDED JUNE 30, |
|
|
3 MONTHS ENDED JUNE 30, |
|
| |
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
| Comprehensive net loss |
|
$ |
(4,489 |
) |
|
$ |
(1,170 |
) |
|
$ |
(4,489 |
) |
|
$ |
(1,170 |
) |
| Net Loss per common share - basic |
|
$ |
(0.82 |
) |
|
$ |
(0.27 |
) |
|
$ |
(16.40 |
) |
|
$ |
(5.43 |
) |
| Net Loss per common share - diluted |
|
$ |
(0.82 |
) |
|
$ |
(0.27 |
) |
|
$ |
(16.40 |
) |
|
$ |
(5.43 |
) |
| Weighted average common shares outstanding - basic |
|
|
5,475,748 |
|
|
|
4,312,294 |
|
|
|
273,788 |
|
|
|
215,615 |
|
| Weighted average common shares outstanding - diluted |
|
|
5,475,748 |
|
|
|
4,312,294 |
|
|
|
273,788 |
|
|
|
215,615 |
|
| Common stock outstanding at period end |
|
|
5,478,436 |
|
|
|
4,178,274 |
|
|
|
273,922 |
|
|
|
208,914 |
|
| |
|
In thousands of US Dollars |
|
| |
|
(except stock and per stock amounts) |
|
| |
|
PRE SPLIT (3) |
|
|
POST SPLIT (3) |
|
| |
|
6 MONTHS ENDED JUNE 30, |
|
|
6 MONTHS ENDED JUNE 30, |
|
| |
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
| Comprehensive net loss |
|
$ |
(7,410 |
) |
|
$ |
(2,451 |
) |
|
$ |
(7,410 |
) |
|
$ |
(2,451 |
) |
| Net Loss per common share - basic |
|
$ |
(1.42 |
) |
|
$ |
(0.66 |
) |
|
$ |
(28.31 |
) |
|
$ |
(13.23 |
) |
| Net Loss per common share - diluted |
|
$ |
(1.42 |
) |
|
$ |
(0.66 |
) |
|
$ |
(28.31 |
) |
|
$ |
(13.23 |
) |
| Weighted average common shares outstanding - basic |
|
|
5,234,765 |
|
|
|
3,706,510 |
|
|
|
261,739 |
|
|
|
185,326 |
|
| Weighted average common shares outstanding - diluted |
|
|
5,234,765 |
|
|
|
3,706,510 |
|
|
|
261,739 |
|
|
|
185,326 |
|
| Common stock outstanding at period end |
|
|
5,478,436 |
|
|
|
4,178,274 |
|
|
|
273,922 |
|
|
|
208,914 |
|
| |
|
In thousands of US Dollars |
|
| |
|
(except stock and per stock amounts) |
|
| |
|
PRE SPLIT (4) |
|
|
POST SPLIT (4) |
|
| |
|
3 MONTHS ENDED SEPTEMBER 30, |
|
|
3 MONTHS ENDED SEPTEMBER 30, |
|
| |
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
| Comprehensive net loss |
|
$ |
(5,104 |
) |
|
$ |
(2,217 |
) |
|
$ |
(5,104 |
) |
|
$ |
(2,217 |
) |
| Net Loss per common share - basic |
|
$ |
(0.91 |
) |
|
$ |
(0.49 |
) |
|
$ |
(18.25 |
) |
|
$ |
(9.65 |
) |
| Net Loss per common share - diluted |
|
$ |
(0.91 |
) |
|
$ |
(0.49 |
) |
|
$ |
(18.25 |
) |
|
$ |
(9.65 |
) |
| Weighted average common shares outstanding - basic |
|
|
5,594,880 |
|
|
|
4,593,733 |
|
|
|
279,744 |
|
|
|
229,687 |
|
| Weighted average common shares outstanding - diluted |
|
|
5,594,880 |
|
|
|
4,593,733 |
|
|
|
279,744 |
|
|
|
229,687 |
|
| Common stock outstanding at period end |
|
|
5,772,026 |
|
|
|
4,178,274 |
|
|
|
288,602 |
|
|
|
208,914 |
|
| |
|
In thousands of US Dollars |
|
| |
|
(except stock and per stock amounts) |
|
| |
|
PRE SPLIT (4) |
|
|
POST SPLIT (4) |
|
| |
|
9 MONTHS ENDED SEPTEMBER 30, |
|
|
9 MONTHS ENDED SEPTEMBER 30, |
|
| |
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
| Comprehensive net loss |
|
$ |
(12,514 |
) |
|
$ |
(4,668 |
) |
|
$ |
(12,514 |
) |
|
$ |
(4,668 |
) |
| Net Loss per common share - basic |
|
$ |
(2.39 |
) |
|
$ |
(1.38 |
) |
|
$ |
(46.73 |
) |
|
$ |
(23.30 |
) |
| Net Loss per common share - diluted |
|
$ |
(2.39 |
) |
|
$ |
(1.38 |
) |
|
$ |
(46.73 |
) |
|
$ |
(23.30 |
) |
| Weighted average common shares outstanding - basic |
|
|
5,355,806 |
|
|
|
4,006,527 |
|
|
|
267,791 |
|
|
|
200,327 |
|
| Weighted average common shares outstanding - diluted |
|
|
5,355,806 |
|
|
|
4,006,527 |
|
|
|
267,791 |
|
|
|
200,327 |
|
| Common stock outstanding at period end |
|
|
5,772,026 |
|
|
|
4,178,274 |
|
|
|
288,602 |
|
|
|
208,914 |
|
| (1) |
The
pre-split amounts represent the amounts reported in the Company’s Form 10-K filed on March 28, 2024. The post-split amounts include
the effects of the 1 for 5 reverse stock split completed in May 2024 and the effects of the 1 for 20 reverse stock split completed
in 2025. |
| (2) |
The
pre-split amounts represent the amounts reported in the Company’s Form 10-Q filed on May 15, 2024. The post-split amounts include
the effects of the 1 for 5 reverse stock split completed in May 2024 and the effects of the 1 for 20 reverse stock split completed
in February 2025. |
| (3) |
The
pre-split amounts represent the amounts reported in the Company’s Form 10-Q filed on August 13, 2024. The post-split amounts include
the effects of the 1 for 20 reverse stock split completed in February 2025. |
| (4) |
The
pre-split amounts represent the amounts reported in the Company’s Form 10-Q filed on November 14, 2024. The post-split amounts include
the effects of the 1 for 20 reverse stock split completed in February 2025. |
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| Date:
February 4, 2025 |
|
| |
|
| |
GLUCOTRACK,
INC. |
| |
|
|
| |
By: |
/s/
Paul Goode |
| |
Name: |
Paul
Goode |
| |
Title: |
Chief
Executive Officer |
Exhibit
3.1
CERTIFICATE
OF AMENDMENT
OF
CERTIFICATE OF INCORPORATION
OF
GLUCOTRACK, INC.
Glucotrack,
Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify
as follows:
1.
The name of the Corporation is Glucotrack, Inc.
2.
The Certificate of Incorporation of the Corporation is amended by replacing Article IV with the following:
“The
total number of shares of common stock which the Corporation is authorized to issue is 250,000,000 shares, par value $0.001 per share
(“Common Stock”), and the total number of shares of preferred stock which the Corporation is authorized to issue is 10,000,000
shares, par value $0.001 per share.
The
Board of Directors of the Corporation is hereby expressly authorized to provide, out of the unissued shares of preferred stock, for one
or more series of preferred stock and, with respect to each such series, to fix the number of shares constituting such series and the
designation of such series, the voting powers, if any, of the shares of such series, and the preferences and relative, participating,
optional or other special rights, if any, and any qualifications, limitations or restrictions thereof, of the shares of such series.
The powers, preferences and relative, participating, optional and other special rights of each series of preferred stock, and the qualifications,
limitations or restrictions thereof, if any, may differ from those of any and all other series at any time outstanding.
Upon
the filing and effectiveness (the “Effective Time”) of this amendment to the Corporation’s Certificate of Incorporation,
as amended, pursuant to the Delaware General Corporation Law, each 20 shares of the Common Stock issued immediately prior to the Effective
Time (the “Old Common Stock”) shall be reclassified and combined into one validly issued, fully paid and non-assessable share
of the Corporation’s Common Stock, $0.001 par value per share (the “New Common Stock”), without any action by the holder
thereof, subject to the treatment of fractional share interests as described below (the “Reverse Stock Split”). No fractional
shares of New Common Stock shall be issued as a result of the Reverse Stock Split and, any person who would otherwise be entitled to
a fractional share of New Common Stock as a result of the Reverse Stock Split, following the Effective Time, shall be entitled to receive
a whole share of New Common Stock in lieu of any fractional share created as a result of such Reverse Stock Split. Each book entry position
that theretofore represented shares of Old Common Stock shall thereafter represent that number of shares of New Common Stock into which
the shares of Old Common Stock represented by such book entry position shall have been reclassified and combined; provided, that each
person holding of record a book entry position that represented shares of Old Common Stock shall receive, a new book entry position evidencing
and representing the number of shares of New Common Stock to which such person is entitled under the foregoing reclassification and combination.
The
Reverse Stock Split shall not affect the total number of shares of capital stock, including the Common Stock, that the Corporation is
authorized to issue, which shall remain as set forth under this Article IV.”
3.
This Certificate of Amendment has been duly adopted by the Board of Directors and stockholders of the Corporation in accordance with
Section 242 of the General Corporation Law of the State of Delaware.
4.
This Certificate of Amendment shall become effective as of 4:30 P.M., Eastern Time on February 3, 2025.
IN
WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be duly executed in its corporate name as of the 3rd
day of February, 2025.
| |
GLUCOTRACK, INC. |
| |
|
|
| |
By: |
/s/
Paul V. Goode |
| |
Name: |
Paul
V. Goode |
| |
Name: |
Chief
Executive Officer |
Exhibit 99.1
GLUCOTRACK
ANNOUNCES SUCCESSFUL COMPLETION OF ITS FIRST HUMAN CLINICAL STUDY OF CONTINUOUS BLOOD GLUCOSE MONITOR
The study
met its primary endpoint with no procedure or device
related serious
adverse events reported
Rutherford,
NJ, February 4, 2025 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”),
a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes,
announced the successful completion of its first in human clinical study, marking a significant milestone in continuous glucose monitoring.
This study represents
the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose
measurement without the limitations often seen with traditional continuous glucose monitors that measure glucose levels in interstitial
fluid.
“We are
thrilled with the results of this first in human clinical study, which establishes safety of the placement, usage and removal of the CBGM
sensor lead. While neither the study nor prototype system was designed to evaluate sensor accuracy, the system performed as expected with
similar accuracy results as previously seen in our animal studies,” said Paul V. Goode, PhD, President & Chief Executive Officer
of Glucotrack. “With these positive results, the promise of continuous blood glucose monitoring is one step closer to reality.”
The prospective
single arm study was a short-term in-hospital study over a period of four days, focusing on the safety and procedural aspects of the CBGM
sensor lead placement, use, and removal. The CBGM sensor lead was placed intravascularly via a percutaneous procedure and connected to
a prototype sensor electronics component that was placed on the skin. The six study participants had been previously diagnosed with diabetes
mellitus requiring glucose monitoring and intensive insulin therapy.
The study met
its primary endpoint with no procedure or device related serious adverse events reported from implant through seven days post-removal
of the CBGM sensor lead. The study also confirmed the function of the CBGM sensor lead in the subclavian vein. Placement and removal procedures
were successfully performed by interventional cardiologists.
David Klonoff, MD, Clinical Professor of Medicine
at University of California, San Francisco and Editor-in-Chief of the Journal of Diabetes Science and Technology, said “The successful
completion of this first in human study with no serious adverse events is encouraging. The study suggests that this approach could offer
another alternative for continuously monitoring glucose levels in diabetes, and I look forward to seeing this technology advance into
long-term clinical trials.”
The CBGM is
a long-term implantable device with no on-body external component, designed for three years of continuous, accurate blood glucose monitoring,
offering a more convenient and less intrusive glucose monitoring solution.
For more information
about Glucotrack’s CBGM, visit glucotrack.com. Information on the Company’s
website does not constitute a part of and is not incorporated by reference into this press release.
# # #
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ:
GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently
developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.
Glucotrack’s
CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body
wearable component and with minimal calibration. For more information, please visit http://www.glucotrack.com.
Forward-Looking Statements
This news release contains
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news
release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of
the foregoing, words such as “believe”, “expect”, “plan” and “will” are intended to identify
forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and
information currently available to, management. These statements relate only to events as of the date on which the statements are made,
and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future
events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these
cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially
realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that
certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking
statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to,
the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt
financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S.
Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating
to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including
sales and distribution personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and
Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2023 as filed with
the SEC on March 28, 2024.
Contacts:
Investor Relations:
investors@glucotrack.com
Media:
GlucotrackPR@icrinc.com
v3.25.0.1
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
| Name: |
dei_CurrentFiscalYearEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:gMonthDayItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
GlucoTrack (NASDAQ:GCTK)
Historical Stock Chart
From Feb 2025 to Mar 2025
GlucoTrack (NASDAQ:GCTK)
Historical Stock Chart
From Mar 2024 to Mar 2025
